Dechra Pharmaceuticals (LSE:DPH) EV-to-Revenue : 6.34 (As of Apr. 28, 2024)

View and export this data going back to 2000. Start your Free Trial

What is Dechra Pharmaceuticals EV-to-Revenue?

EV-to-Revenue is calculated as enterprise value divided by its revenue. As of today, Dechra Pharmaceuticals's enterprise value is £4,831.4 Mil. Dechra Pharmaceuticals's Revenue for the trailing twelve months (TTM) ended in Jun. 2023 was £761.5 Mil. Therefore, Dechra Pharmaceuticals's EV-to-Revenue for today is 6.34.

The historical rank and industry rank for Dechra Pharmaceuticals's EV-to-Revenue or its related term are showing as below:

LSE:DPH' s EV-to-Revenue Range Over the Past 10 Years
Min: 3.14 Med: 5.97 Max: 9.93
Current: 6.34

During the past 13 years, the highest EV-to-Revenue of Dechra Pharmaceuticals was 9.93. The lowest was 3.14. And the median was 5.97.

LSE:DPH's EV-to-Revenue is not ranked
in the Drug Manufacturers industry.
Industry Median: 2.29 vs LSE:DPH: 6.34

The reason Enterprise Value is used is because Enterprise Value is more real in reflecting how much an investor pays when buying a company. For detais, go to Enterprise Value.

EV-to-Revenue is a similar ratio to PS Ratio, except here Enterprise Value instead of Market Cap is used in the calculation.

As of today (2024-04-28), Dechra Pharmaceuticals's stock price is £38.66. Dechra Pharmaceuticals's Revenue per Share for the trailing twelve months (TTM) ended in Jun. 2023 was £6.68. Therefore, Dechra Pharmaceuticals's PS Ratio for today is 5.79.

Dechra Pharmaceuticals EV-to-Revenue Historical Data

The historical data trend for Dechra Pharmaceuticals's EV-to-Revenue can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

* Premium members only.

Dechra Pharmaceuticals EV-to-Revenue Chart

Dechra Pharmaceuticals Annual Data

Trend

Jun14

Jun15

Jun16

Jun17

Jun18

Jun19

Jun20

Jun21

Jun22

Jun23

EV-to-Revenue

Get a 7-Day Free Trial

6.32

6.22

8.11

5.80

6.08

Dechra Pharmaceuticals Semi-Annual Data
	Dec13	Jun14	Dec14	Jun15	Dec15	Jun16	Dec16	Jun17	Dec17	Jun18	Dec18	Jun19	Dec19	Jun20	Dec20	Jun21	Dec21	Jun22	Dec22	Jun23
EV-to-Revenue	Get a 7-Day Free Trial															8.11	-	5.80	-	6.08

Competitive Comparison of Dechra Pharmaceuticals's EV-to-Revenue

For the Drug Manufacturers - General subindustry, Dechra Pharmaceuticals's EV-to-Revenue, along with its competitors' market caps and EV-to-Revenue data, can be viewed below:

* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.

Dechra Pharmaceuticals's EV-to-Revenue Distribution in the Drug Manufacturers Industry

For the Drug Manufacturers industry and Healthcare sector, Dechra Pharmaceuticals's EV-to-Revenue distribution charts can be found below:

* The bar in red indicates where Dechra Pharmaceuticals's EV-to-Revenue falls into.

Dechra Pharmaceuticals EV-to-Revenue Calculation

EV-to-Revenue is a similar ratio to PS Ratio, except here Enterprise Value instead of Market Cap is used in the calculation.

Dechra Pharmaceuticals's EV-to-Revenue for today is calculated as:

EV-to-Revenue	=	Enterprise Value (Today)	/	Revenue (TTM)
	=	4831.424	/	761.5
	=	6.34

Dechra Pharmaceuticals's current Enterprise Value is £4,831.4 Mil.
For company reported semi-annually, GuruFocus uses latest annual data as the TTM data. Dechra Pharmaceuticals's Revenue for the trailing twelve months (TTM) ended in Jun. 2023 was £761.5 Mil.

Dechra Pharmaceuticals (LSE:DPH) EV-to-Revenue Explanation

The reason Enterprise Value is used is because Enterprise Value is more real in reflecting how much an investor pays when buying a company. For detais, go to Enterprise Value.

Dechra Pharmaceuticals's PS Ratiofor today is calculated as:

PS Ratio	=	Share Price (Today)	/	Revenue per Share (TTM)
	=	38.66	/	6.675
	=	5.79

Dechra Pharmaceuticals's share price for today is £38.66.
For company reported semi-annually, GuruFocus uses latest annual data as the TTM data. {COMPANY->company}'s Revenue per Sharefor the trailing twelve months (TTM) ended in Jun. 2023 was £6.68.

Dechra Pharmaceuticals EV-to-Revenue Related Terms

Thank you for viewing the detailed overview of Dechra Pharmaceuticals's EV-to-Revenue provided by GuruFocus.com. Please click on the following links to see related term pages.

Dechra Pharmaceuticals (LSE:DPH) Business Description

Industry

GURUFOCUS.COM » STOCK LIST » Healthcare » Drug Manufacturers » Dechra Pharmaceuticals PLC (LSE:DPH) » Definitions » EV-to-Revenue

Comparable Companies

Traded in Other Exchanges

DPHAY:USA DPHl:UK 1PK:Germany

Address

24 Cheshire Avenue, Cheshire Business Park, Lostock Gralam, Northwich, GBR, CW9 7UA

Website

https://www.dechra.com

Dechra Pharmaceuticals PLC is a major drug manufacturing company with a focus on veterinary pharmaceutical products. The company develops, manufactures, and markets its products exclusively for veterinarians globally. Dechra is structured along three segments, including being European Pharmaceuticals, North American Pharmaceuticals, and Pharmaceuticals Research and Development. The vast majority of Dechra's revenue is generated in Europe, followed by the U.S. Dechra derives most of its revenue through its Companion Animal Product category, followed by food-producing animal products.

Dechra Pharmaceuticals (LSE:DPH) Headlines

No Headlines